

Aug 13, 2025 8:00 AM Eastern Daylight Time

Shore Capital Partners Announces Formation of PhaseWell Research and Welcomes Gabrail Cancer Center Research and Renstar Medical Research

PhaseWell is dedicated to bringing high-quality clinical trials closer to the communities it serves—broadening access and accelerating medical innovation.

CHICAGO--([BUSINESS WIRE](#))--Shore Capital Partners (“Shore” or “Shore Capital”), a Chicago-based private equity firm with offices in Nashville, today announced the formation of PhaseWell Research (“PhaseWell” or the “Company”), a clinical research site company united by a shared commitment to advance the future of medicine.

Headquartered in Nashville, Tennessee, PhaseWell Research is dedicated to increasing participation in clinical trials by making research more accessible to patients across the country. The company aims to bring high-quality clinical trials closer to the communities it serves, broadening access and accelerating medical innovation.

PhaseWell is built on a foundation of trusted, high-performing research sites with longstanding reputations in the life sciences industry. Its network includes industry leaders such as Renstar Medical Research (RMR) and Gabrail Cancer Center Research (GCCR), both known for decades of expertise and consistent delivery of high-quality results across complex therapeutic areas. Backed by a team of more than 70 professionals, over 28 years of clinical research experience, and with a growing footprint nationwide, PhaseWell brings meaningful value to the clinical development process.

With more than 1,400 clinical trials completed and contributions to the approval of over 150 therapies, PhaseWell provides comprehensive Phase I–IV trial services across a wide range of therapeutic areas. Current areas of focus include oncology, central nervous system (CNS), cardiovascular/metabolic, and dermatology.

Carsten Bick, a 15-year healthcare veteran, has been appointed PhaseWell’s Chief Executive Officer. Bick spent a decade in health system and payor services prior to leading national operations for IVX Health, a 140+ location ambulatory infusion company focused on providing infusible and injectable biologics to patients with complex chronic conditions.

“PhaseWell is unique in that we not only own and operate dedicated research sites but also enable research within carefully selected partners in our growing community practice network,” said Bick. “We are driven by the urgent need to help solve growing challenges in this end of the value chain. Faster study start-up, improved patient recruitment, and higher-integrity data are required to ensure sponsor protocols are executed in an increasingly

complex R&D environment. For our patient population, quality research represents access to potentially life-changing therapies not commercially available in the market today.”

“We have spent the last several decades hyper-focused on delivering the best community-based cancer research to Northeast Ohio. Joining PhaseWell Research enables us to further scale our research capabilities outside of Ohio while doubling down on what makes us so successful for our patients locally,” said Dr. Nashat Gabrail, founder and leading primary investigator at Gabrail Cancer Center Research.

“Partnering with PhaseWell enables us to expand clinical trial opportunities in our community, strengthen relationships with patients and local physicians, and continue delivering the trusted care and high-quality research Renstar is known for,” said Aaron Campo, President and Co-Founder at Renstar Medical Research.

“Our strategy centers on partnering with outstanding operators, empowering top-tier leadership, assembling world-class boards, and providing the resources needed to grow. The clinical research site space is a natural fit for Shore, and we’ve consistently demonstrated our ability to scale complex multi-site healthcare and pharma services businesses,” said Ankeet Patel, Vice President at Shore Capital. “With the deep operational experience and scientific talent across the PhaseWell platform - combined with Shore’s resources and support - we believe PhaseWell Research is well-positioned to become a trusted partner to pharmaceutical companies, biotech firms, and CROs alike,” added John Hennegan, Founding Partner at Shore Capital.

To learn more about [PhaseWell Research](#), please visit www.phasewell.com or contact info@phasewell.com.

About PhaseWell Research

PhaseWell Research is a clinical research site company united by a shared commitment to advance the future of medicine. With a national network of high-performing sites, PhaseWell delivers comprehensive Phase I–IV clinical trial services across a broad range of therapeutic areas—including oncology, central nervous system (CNS), cardiovascular/metabolic, and dermatology. PhaseWell’s team of physicians and investigators are recognized industry leaders, known for their clinical expertise and operational excellence. By leveraging proven recruitment strategies and deep access to diverse patient populations through robust databases and strategic partnerships, PhaseWell has successfully completed more than 1,400 clinical trials and contributed to the approval of over 150 therapies. To learn more about PhaseWell Research, please visit www.phasewell.com.

About Gabrail Cancer Center Research

Gabrail Cancer Center Research (GCCR) is a nationally recognized clinical research site dedicated to advancing oncology care through cutting-edge clinical trials. Founded by Dr. Nashat Gabrail in Canton, Ohio, GCCR has built a reputation over two decades for scientific excellence, rapid study start-up, and high-integrity data collection. Specializing in Phase I–IV oncology trials, GCCR provides access to innovative therapies for patients within a community-based setting. The center’s robust clinical infrastructure, diverse patient population, and commitment to patient-centric research have enabled it to participate in hundreds of oncology trials, including many first-in-human and novel combination studies. GCCR continues to contribute meaningfully to the global fight against cancer by bridging scientific discovery with real-world patient access. To learn more about Gabrail Cancer Center Research, please visit www.gabrailcancercenter.com/clinical-trials.

About Renstar Medical Research

Renstar Medical Research is a standalone, community-based clinical research site headquartered in Ocala, North-Central Florida. Since its founding in 1998, Renstar has earned a reputation for ethical, high-quality execution of Phase I–IV clinical trials across therapeutic areas including Alzheimer’s disease, psoriasis, osteoarthritis, migraine, fibromyalgia, hypertension, diabetes, and more. Serving one of the fastest-growing retirement regions in the country, Renstar works alongside local physicians in private practice and community hospital settings to deploy a multidisciplinary operations model that is both responsive and patient-centric. Renstar’s highly trained staff, best-in-class patient recruitment capabilities, and depth of community engagement position the Company to be a trusted research partner to leading biopharmaceutical companies and CROs. To learn more about Renstar Medical Research, please visit www.renstar.net.

About Shore Capital Partners

Shore Capital, a Chicago-based private equity firm with offices in Nashville, is an investor in lower middle market companies in the Healthcare, Food and Beverage, Business Services, Industrial, and Real Estate industries. Shore’s strategy is to support management partners to grow faster with less risk through access to capital, world-class board and operational resources, and unmatched networking, development, and shared learnings across the portfolio. From 2020-2024, Shore received recognition from Inc Magazine as a 5x Top Founder Friendly Investor and by Pitchbook Research for leading U.S. Private Equity deal volume for the past 10 years, from 2015-2024. Shore targets investments in proven, successful private companies with superior management teams, stable cash flow, and significant potential to grow through industry consolidation and organic growth to generate value for shareholders. Shore has approximately \$13 billion of assets under management

and in additional investment platforms to which it provides business and operational consulting services. To learn more about Shore Capital Partners, please visit www.shorecp.com

Contacts

info@phasewell.com